[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635939":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":45,"collaborators":20,"id":48,"slug":20,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":20,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":20,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Guilin Medical University, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ACP3 PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of radiolabeld ACP3 and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: standard-of-care imaging (PSMA\u002FFDG PET\u002FCT), ACP3 PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","standard-of-care imaging (PSMA\u002FFDG PET\u002FCT), ACP3 PET\u002FCT","Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (PSMA\u002FFDG) and ACP3, and undergoes PET\u002FCT imaging within the specified time.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Xingyu Mu, PhD","CONTACT","86 13347631119","muxingyu1992@hotmail.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Wei Fu","86 13977385850","fuwei19700513@163.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":20},"The First Affliated Hospital of Guilin Medical University","RECRUITING","Guilin","Guangxi","541001","China",{"type":40,"coordinates":41},"Point",[42,43],110.29639,25.28022,{"lat":43,"lon":42},{"type":46,"investigatorFullName":28,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Department of Nuclear Medicine","100635939",false,"NCT07559201","Theranostic Applications of Radionuclides in Prostate Cancer","ACP3 Targeted -PET\u002F CT in Prostate Cancer","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);\n* Patients who had scheduled both standard-of-care imaging (PSMA\u002FFDG PET\u002FCT) and ACP3 PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* The inability or unwillingness of the research participant or legal representative to provide written informed consent.","MALE","18 Years",{"count":57,"type":58},100,"ESTIMATED","INTERVENTIONAL",[61],"NA","The objective of the study is to construct a noninvasive approach ACP3 targeted PET\u002FCT to detect tumor lesions in patients with prostate cancer and to compare with PSMA\u002FFDG PET\u002FCT.",[64],"Prostate Cancer (Diagnosis)",[66,67,68],"prostate cancer","PET\u002FCT","ACP3","2026-04-23",{"date":71,"type":72},"2026-04-30","ACTUAL",{"date":74,"type":72},"2026-01-01",{"date":76,"type":58},"2029-12-31",{"name":5,"class":6},1]